Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial

医学 浆液性液体 随机对照试验 阶段(地层学) 人口 癌症 妇科 卵巢癌 内科学 肿瘤科 生物 环境卫生 古生物学
作者
Usha Menon,Aleksandra Gentry‐Maharaj,Matthew Burnell,Andy Ryan,Naveena Singh,Ranjit Manchanda,Jatinderpal Kalsi,Robert Woolas,Rupali Arora,Laura Casey,Anne Dawnay,Aarti Sharma,Karin Williamson,Sophia Apostolidou,Lesley Fallowfield,Alistair McGuire,Stuart Campbell,Steven J. Skates,Ian Jacobs,Mahesh Parmar
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (9): 1018-1028 被引量:13
标识
DOI:10.1016/s1470-2045(23)00335-2
摘要

BackgroundIn UKCTOCS, there was a decrease in the diagnosis of advanced stage tubo-ovarian cancer but no reduction in deaths in the multimodal screening group compared with the no screening group. Therefore, we did exploratory analyses of patients with high-grade serous ovarian cancer to understand the reason for the discrepancy.MethodsUKCTOCS was a 13-centre randomised controlled trial of screening postmenopausal women from the general population, aged 50–74 years, with intact ovaries. The trial management system randomly allocated (2:1:1) eligible participants (recruited from April 17, 2001, to Sept 29, 2005) in blocks of 32 using computer generated random numbers to no screening or annual screening (multimodal screening or ultrasound screening) until Dec 31, 2011. Follow-up was through national registries until June 30, 2020. An outcome review committee, masked to randomisation group, adjudicated on ovarian cancer diagnosis, histotype, stage, and cause of death. In this study, analyses were intention-to-screen comparisons of women with high-grade serous cancer at censorship (Dec 31, 2014) in multimodal screening versus no screening, using descriptive statistics for stage and treatment endpoints, and the Versatile test for survival from randomisation. This trial is registered with the ISRCTN Registry, 22488978, and ClinicalTrials.gov, NCT00058032.Findings202 562 eligible women were recruited (50 625 multimodal screening; 50 623 ultrasound screening; 101 314 no screening). 259 (0·5%) of 50 625 participants in the multimodal screening group and 520 (0·5%) of 101 314 in the no screening group were diagnosed with high-grade serous cancer. In the multimodal screening group compared with the no screening group, fewer were diagnosed with advanced stage disease (195 [75%] of 259 vs 446 [86%] of 520; p=0·0003), more had primary surgery (158 [61%] vs 219 [42%]; p<0·0001), more had zero residual disease following debulking surgery (119 [46%] vs 157 [30%]; p<0·0001), and more received treatment including both surgery and chemotherapy (192 [74%] vs 331 [64%]; p=0·0032). There was no difference in the first-line combination chemotherapy rate (142 [55%] vs 293 [56%]; p=0·69). Median follow-up from randomisation of 779 women with high-grade serous cancer in the multimodal and no screening groups was 9·51 years (IQR 6·04–13·00). At censorship (June 30, 2020), survival from randomisation was longer in women with high-grade serous cancer in the multimodal screening group than in the no screening group with absolute difference in survival of 6·9% (95% CI 0·4–13·0; p=0·042) at 18 years (21% [95% CI 15·6–26·2] vs 14% [95% CI 10·5–17·4]).InterpretationTo our knowledge, this is the first evidence that screening can detect high-grade serous cancer earlier and lead to improved short-term treatment outcomes compared with no screening. The potential survival benefit for women with high-grade serous cancer was small, most likely due to only modest gains in early detection and treatment improvement, and tumour biology. The cumulative results of the trial suggest that surrogate endpoints for disease-specific mortality should not currently be used in screening trials for ovarian cancer.FundingNational Institute for Health Research, Medical Research Council, Cancer Research UK, The Eve Appeal.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2397完成签到,获得积分20
1秒前
今后的应助被淡定的板栗采纳,获得10
1秒前
huoo发布了新的文献求助10
2秒前
2秒前
做完实验打boss完成签到,获得积分10
2秒前
臭屁发布了新的文献求助10
2秒前
Nole的应助被精明丹妗采纳,获得10
2秒前
赵妍发布了新的文献求助10
2秒前
2秒前
3秒前
L912294993完成签到,获得积分10
3秒前
自然的小鸭子完成签到,获得积分10
4秒前
4秒前
zj发布了新的文献求助10
4秒前
单薄雪巧发布了新的文献求助10
4秒前
乐乐的应助被herococa采纳,获得10
4秒前
keyan完成签到,获得积分10
4秒前
大方的契发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
orixero的应助被Seorina采纳,获得10
6秒前
年轻山河完成签到 ,获得积分10
7秒前
传奇3的应助被十一采纳,获得10
7秒前
传奇3的应助被动人的臻采纳,获得10
7秒前
tomatoGG发布了新的文献求助10
7秒前
Kin发布了新的文献求助10
8秒前
李天王发布了新的文献求助10
9秒前
Akim的应助被初海歌采纳,获得10
10秒前
小叮当完成签到,获得积分10
10秒前
11秒前
3503264269发布了新的文献求助10
11秒前
领导范儿的应助被番茄炒蛋采纳,获得30
11秒前
12秒前
Felicia完成签到,获得积分10
12秒前
13秒前
13秒前
14秒前
Nole的应助被唐润妍采纳,获得10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193335
求助须知:如何正确求助?哪些是违规求助? 9579489
关于积分的说明 21865844
捐赠科研通 7792843
什么是DOI,文献DOI怎么找? 3437210
关于科研通互助平台的介绍 2560687
邀请新用户注册赠送积分活动 2483996